A/Prof Mastura Monif

Purinergic P2X receptor 7 (P2X7R) inhibition induced cytotoxicity in glioblastoma Glioblastoma is the most common and aggressive form of primary brain cancer with a median survival of 15 months from diagnosis. The purinergic receptor P2X7 (P2X7R) is a regulator of several cell sign...

NEW in @plosone.org promising #glioblastoma therapeutic target. Dr Matthew Drill & team
@masturamonif.bsky.social @monashuniversity.bsky.social
reveal an alternative pathway with selective targeting to complement existing treatments and/or offer new treatment doi.org/10.1371/jour... #neuroscience

Living with Autoimmune Encephalitis YouTube video by Translational Medicine, Monash University

Our public webinar Living with #Autoimmune #Encephalitis is now available on YouTube.
Thanks to Amber, Amanda & Michelle for their enormous courage to share their lived experiences of AE. I am sure the stories will resonate with many others.
@monashstm-grsc.bsky.social

youtu.be/S2B4fe7CwK0?...

Living with Autoimmune Encephalitis Learn about autoimmune encephalitis & hear personal stories of coping & thriving while living with this rare condition.

#AutoimmuneEncephalitis can induce longlasting and pervasive impacts. On Tuesday 11th of March, we are hosting a webinar featuring those with lived experiences of AE.

Link below to register:
events.humanitix.com/understandin...

Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG–Positive NMOSD | Neurology ObjectivesIn aquaporin-4 antibody–positive neuromyelitis optica spectrum disorder (AQP4-IgG NMOSD), disability accrual is mostly attributed to relapses. This study aimed to assess the prevalence of pr...

Does progression occur independent of relapses (#PIRA) in neuromyelitis optica (#NMOSD)? Our PhD student Pakeeran Siriratnam examined this in real-world data & by tracking data on each progression event. @masturamonif.bsky.social @vjokubaitis.bsky.social

www.neurology.org/doi/10.1212/...

Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology This narrative review explores the current and future roles of chimeric antigen receptor (CAR) T-cell therapy in neurology, particularly for primary brain tumors and autoimmune neurological disorders.

Alfred Health MSNI with Alfred Haematology is proud and excited to be one of two sites in Australia to offer #CARTcell therapy for aggressive relapsing and also progressive forms of #MS. @masturamonif.bsky.social

jamanetwork.com/journals/jam...